Phase 1 N=50 Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis
COVID-19 · Pharmacokinetics · Safety
Primary: Number of Participants With Related Grade 2 or Higher Adverse Events — 6; 2; 27; 15 Participants — p=.70
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=46 Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Childhood Solid Neoplasm · Recurrent Childhood Anaplastic Large Cell Lymphoma · Recurrent Neuroblastoma
Primary: Maximum Tolerated Dose (MTD) of Crizotinib — 215 mg/m^2
N/A N=384 Post-resection Treatment of Large Colon Polyps
Recurrence
Primary: Recurrence — 10; 5; 24 Polyps
N/A N=86 Improving Health Insurance Experiences for Adolescent and Young Adult Cancer Patients
Adolescent · Young Adult · Cancer
Primary: Feasibility Measurement — 39; 25 Participants
Phase 2 N=2 A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Mesothelioma · Peritoneal Mesothelioma
Primary: Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery
Phase 2 N=10 PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
Small Cell Lung Cancer · Extra-Pulmonary Small Cell Carcinomas
Primary: Phase II: Clinical Benefit Rate
Phase 2 N=25 A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
Polymyositis · Dermatomyositis
Primary: Mean Change in the Total Improvement Score (TIS) From Start to End of Zetomipzomib (KZR-616) Treatment Period — 25.5; 25.0; 33.1; 33.5 score on a scale
Phase 2 N=42 Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Lymphoma
Primary: Objective Response Rate (ORR) — 88.1 percentage of participants
Phase 3 N=13,970 Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
Cardiovascular Diseases · Statin Adverse Reaction
Primary: Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE) — 819; 927 Participants — p=0.004
N/A N=143 HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists
COVID
Primary: Number of Participants With SARS-CoV-2 IgG Antibodies — 14 Participants
Phase 2 N=221 A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
Dermatitis, Atopic · Eczema
Primary: Mean Percentage Change From Baseline in EASI at Week 16 — -84.41; -76.03; -78.93; -62.65 Percent Change — p=0.003
Phase 1 N=46 Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Diffuse Intrinsic Pontine Glioma
Primary: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose of Adavosertib — 200 mg/m^2
N/A N=202 Hypertension In Postpartum Preeclampsia Study
Hypertension, Pregnancy-Induced
Primary: Average Mean Arterial Blood Pressure- Mild Group — 93; 93 mmHg
Phase 2 N=16 Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
Primary: Percent Change From Baseline in Lactate Dehydrogenase (LDH) Level at Day 92 — -53.59; -25.56; -43.58 Percent change from Baseline
Phase 1 N=28 Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649
Healthy
Primary: Cmax — 11.0; 107 ng/mL